Carbotor 150 MG (Carboplatin) Injection

Introduction

The Carbotor 150 mg (Carboplatin) Injection is a platinum-based alkylating chemotherapy agent designed for the treatment of advanced ovarian carcinoma. Manufactured by Eskayef Pharmaceuticals Ltd., a leader in high-quality pharmaceutical solutions, and supplied by Onco Solution, a global oncology medicine provider, Carbotor offers targeted efficacy with reduced renal toxicity compared to traditional platinum therapies. Whether used as initial combination therapy or for palliative care in recurrent cases, this injection is a cornerstone in ovarian cancer management, balancing potency with patient safety.

Key Benefits

Effective Tumor Suppression – Disrupts DNA synthesis in cancer cells through covalent DNA binding, inhibiting tumor growth.
Reduced Renal Toxicity – Unlike cisplatin, Carbotor minimizes kidney damage, eliminating the need for aggressive hydration protocols.
Versatile Application – Suitable for both initial treatment (combined with cyclophosphamide) and secondary treatment of recurrent ovarian carcinoma.

Indications

1. Initial Treatment of Advanced Ovarian Carcinoma

Carbotor 150 mg (Carboplatin) Injection is indicated for advanced ovarian carcinoma as part of a combination regimen with other chemotherapeutic agents (e.g., cyclophosphamide).
Supported by randomized NCIC and SWOG studies demonstrating equivalent survival outcomes compared to cisplatin-based therapies.

2. Secondary Treatment of Recurrent Ovarian Carcinoma

Effective for palliative care in patients with recurrent ovarian carcinoma, including those previously treated with cisplatin.
Note: Patients who developed progressive disease during prior cisplatin therapy may show reduced response rates.

Pharmacology

Mechanism of Action: Carboplatin, the active ingredient in Carbotor 150 mg (Carboplatin) Injection, is an alkylating agent that covalently binds to DNA, disrupting cell cycle progression and triggering apoptosis in cancer cells.
Key Advantage: Exhibits significantly lower nephrotoxicity compared to cisplatin, simplifying treatment protocols.

Dosage & Administration

Previously Untreated Patients

Recommended Dose: 400 mg/m² administered as a single short-term IV infusion over 15–60 minutes.
Dosing Interval: Repeat every 4 weeks, provided:
- Neutrophil count ≥ 2,000 cells/mm³.
- Platelet count ≥ 100,000 cells/mm³.

Patients with Prior Myelosuppressive Therapy or Poor Performance Status

Adjusted Dose: Reduce initial dose by 20–25% (300–320 mg/m²) to mitigate bone marrow suppression risks.

Renal Impairment Adjustments (Non-AUC Dosing)

Creatinine Clearance 41–59 mL/min: Reduce dose to 250 mg/m².
Creatinine Clearance 16–40 mL/min: Reduce dose to 200 mg/m².

Drug Interactions

Live Vaccines: Avoid concurrent use due to potential immune compromise.
Nephrotoxic Agents: Enhanced renal toxicity risk (e.g., aminoglycosides, NSAIDs). Monitor kidney function closely.

Contraindications

Severe bone marrow depression or active bleeding.
History of severe allergic reactions to cisplatin or platinum-containing compounds.

Side Effects

Common:
- Bone marrow suppression (anemia, thrombocytopenia, neutropenia).
- Nausea, vomiting, alopecia, mucositis.
Serious:
- Nephrotoxicity (monitor serum creatinine).
- Ototoxicity, neurotoxicity, severe allergic reactions.

Pregnancy & Lactation

Pregnancy Category D: Carbotor may cause fetal harm. Use only if benefits outweigh risks. Contraception is mandatory during treatment.

Lactation: Discontinue breastfeeding due to potential infant toxicity.

Precautions & Warnings

Bone Marrow Suppression: Regular CBC monitoring required. Delay therapy if counts are suboptimal.
Hypersensitivity Reactions: Premedicate with corticosteroids and antihistamines.
Renal Monitoring: Assess creatinine clearance before and during treatment.

Why Choose Carbotor 150 mg (Carboplatin) Injection?

Trusted Quality: Produced by Eskayef Pharmaceuticals Ltd., a pioneer in Bangladesh’s pharmaceutical sector with 30+ years of excellence.
Global Accessibility: Supplied by Onco Solution, ensuring affordable, reliable access to oncology treatments worldwide.
Patient-Centric Design: Reduced renal toxicity and flexible dosing improve tolerability for diverse patient profiles.

Technical Specifications

Active Ingredient: Carboplatin (150 mg/vial).
Storage: Store at controlled room temperature (20–25°C).
Packaging: Sterile, single-dose vials with tamper-proof seals.

Commitment to Excellence

Eskayef Pharmaceuticals Ltd., part of the Transcom Group, combines innovation with stringent quality standards. Partnering with Onco Solution, they bridge global healthcare gaps by delivering affordable, life-saving oncology therapies.

Conclusion

The Carbotor 150 mg (Carboplatin) Injection is a vital tool in the fight against advanced ovarian carcinoma, offering a balance of efficacy, safety, and accessibility. By choosing this product, healthcare providers and patients align with Eskayef Pharmaceuticals Ltd. and Onco Solution – leaders committed to advancing cancer care through innovation and compassion.